Using drugs such as alcohol and morphine among others can be addictive in some individuals, and progress into a substance abuse disorder. The mesolimbic dopaminergic system (MD-system) is involved in the reward process during the development of drug addiction. The MD-system is critical for survival and affects different behaviors in both man and animal. Neurochemical pathways drive for instance physical activity, food intake, love and reproduction and are part of the natural reward process involved partly in the release of dopamine (DA) into frontal lobes. Within the MD-system opioid receptors throughout the brain are affected by drug intake, and activation of these receptors modulate DA-release in brain regions involved in reward-behavior. The aim of this study was to evaluate gene expression of MOR and DOR within the endogenous opioid system (EO-system) in relation to voluntary physical activity, a natural reinforcer. Further on investigations of the drug alcohol was compared to the natural reinforcer sucrose using voluntary consumption. For both experiments qRT-PCR was used to measure mRNA levels of MOR and DOR from brain areas of interest. We found a small significant up regulation in NAc, PFC and VTA but for DOR in VTA a down regulation in gene expression of physical exercising mice. Additionally these two different genes OPRM1- and the OPRD1- gene are down regulated in VTA and NAc due to alcohol- and sugar-intake. This implicate that the natural reward system and their ORs point in the direction of earlier findings; the opioid receptors have a key role in regulate alcohol intake and the natural rewarding stimuli as food intake.

La gestion de la douleur neuropathique reste un challenge en médecine, malgré le nombre de traitements actuellement disponible. L'expérimentation animale a généré beaucoup d'informations concernant la douleur, mais ces connaissances demeurent insuffisantes pour développer de nouveaux analgésiques plus efficaces tout en restant sécuritaires. La douleur est un symptôme clinique complexe avec de multiples origines, et les mécanismes de douleur centraux et périphériques dépendent de l'évolution de la pathologie. Il est donc essentiel d'investiguer plus profondément les mécanismes moléculaires responsables de l'initiation et du maintien de la douleur, afin de cibler de nouvelles voies de transmission de la nociception plus prometteuses pour soulager la neuropathie et développer de meilleures stratégies thérapeutiques. Ce projet s'est donc intéressé plus particulièrement à la famille des tachykinines issues du gène TAC1 (substance P, ses précurseurs et métabolites, et neurokinine A sont les peptides ciblés pour ce projet de recherche), une famille de neuropeptides qui joue un rôle critique dans la transmission nociceptive. Pour réaliser cette étude, nous avons d'abord développé une stratégie de quantification afin de quantifier les expressions des différents neuropeptides bioactifs cibles, par HPLCMS/ MS. Puisqu'il existe différentes stratégies de quantification des peptides par HPLCMS/ MS, une méthode analytique fiable et robuste était nécessaire pour répondre aux objectifs de recherche. Nous avons développé une méthode utilisant la quantification relative avec un étalon interne stable marqué isotopiquement. En effet, pour quantifier les neuropeptides d'intérêt de l'étude, c'est la stratégie qui s'est avérée la plus reproductible et précise. Suite à la mise au point de la stratégie de quantification, nous avons utilisé des modèles animaux, souvent nécessaires pour faire progresser la recherche scientifique sur la compréhension de la douleur

Thesis (Ph. D.) -- University of Texas Southwestern Medical Center at Dallas, 2004. / Vita. Bibliography: 127-149.

Made available in DSpace on 2015-07-22T20:50:53Z (GMT). No. of bitstreams: 0 Previous issue date: 2011-08-31 / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) / Associação Fundo de Incentivo à Psicofarmacologia (AFIP) / Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) / Introdução: A complexidade da fisiopatologia na Esteatose Hepática Não Alcóolica (EHNA) envolve uma interface entre as adipocinas e a regulação neuroendócrina do balanço energético, incluindo o papel do sistema Neuropeptídeo Y/Proteína agouti relacionada. Objetivo: estabelecer a relação entre a razão NeuropeptídeoY/Proteína relacionada Agouti (AgRP) e a adiponectinemia, bem como avaliar a influência de neuropeptídeos orexígenos nos aspectos nutricionais de adolescentes obesos com EHNA submetidos a uma intervenção interdisciplinar de longo prazo. Métodos: Recrutou-se adolescentes obesos pós-púberes para participarem de uma intervenção interdisciplinar. O grupo foi analisado de acordo com a presença ou não de EHNA pela ultrassonografia (US). As amostras de sangue foram coletadas para a mensuração da glicemia, transaminases hepáticas e perfil lipídico, resistência e sensibilidade insulínica. As concentrações de Adiponectina, NPY e AgRP foram avaliadas por ELISA e a mensuração da gordura visceral e subcutânea pela US. A ingestão alimentar foi aferida por meio de registro alimentar de 3 dias. Resultados: No início da terapia, observou-se que parâmetros clínicos importantes como massa corporal, IMC, gordura visceral, HOMA-IR, QUICKI, triglicérides, VLDL-colesterol e transaminases hepáticas apresentaram-se mais alterados em pacientes com EHNA, os quais melhoram após tratamento. Além disso, a energia total e ingestão de macronutrientes reduziram significativamente em ambos os grupos. Observou-se correlação positiva entre AgRP e a gordura visceral em todos os pacientes, e correlação negativa entre NPY/AgRP com a concentração de adiponectina apenas em adolescentes obesos com EHNA. Ao analisar a influência da dieta nos neuropeptídeos orexígenos, apenas os pacientes com EHNA apresentaram correlação positiva entre a ingestão de ácidos graxos saturados com os neuropeptídeos orexígenos (NPY e AgRP); e carboidrato com NPY. Foi observada correlação positiva entre ingestão de energia, (%) de lipídio e ácidos graxos saturados com o acúmulo de gordura visceral. Conclusão: Os pacientes com EHNA apresentaram parâmetros clínicos mais alterados ao compará-los àqueles que não possuíam esta doença, incluindo a correlação negativa entre adiponectina e NPY/AgRP. Estes resultados sugeriram que adolescentes obesos com EHNA apresentaram perfil inflamatório alterado, o qual pode influenciar na regulação neuroendócrina do balanço energético indicando uma barreira adicional na terapia de redução de peso. Além disso, nossos achados revelaram uma importante influência da composição da dieta no sistema orexígeno, sendo essencial considerar a ingestão excessiva de gordura saturada como um fator determinante para o desenvolvimento de EHNA. / BACKGROUND: The complexity physiophatology in the Non Alcoholic Fatty Liver Disease (NAFLD) involves interplay between adipokines and neuroendocrine regulation of energy balance, including the role of Neuropeptide Y/Agouti Related Protein system. AIM: establishing the relationship between Neuropeptide Y/Agouti Related Protein (NPY/AgRP) ratio and adiponectinemia, as well as to assess the influence of orexigenic neuropeptides in the nutritional aspects of NAFLD obese adolescents submitted to a long-term interdisciplinary approach. METHODS: A group of post-pubescent obese adolescents were recruited and included in the interdisciplinary intervention. The group was analyzed according to the presence or ausence of NAFLD by ultrassonography (US). Blood samples were collected to measure glycemia, hepatic transaminases and lipid profile, insulin resistance and sensitivity. Adiponectin, NPY and AgRP concentrations were measured by ELISA and the measurement of visceral ans subcutaneous fat by US. Food intake was measured using 3-day diet records. RESULTS: It was observed at baseline that important clinical parameters including body weight, BMI, visceral fat, HOMA-IR, QUICKI, triglycerides, VLDL-cholesterol and hepatic transaminases were more altered in NAFLD patients. After the intervention, these parameters, total energy and macronutrient intake were reduced significantly in both groups. The most important finding was the positive correlation between AgRP with visceral fat in all patients, and negative correlation between NPY/AgRP with adiponectin only in NAFLD obese adolescents. Analyzing the influence of the diet in the orexigenic neuropeptides, only the NAFLD patients presented a positive correlation between the saturated fatty acids intake and the orexigenic neuropeptides (NPY and AgRP); and carbohydrate with NPY. Indeed, it was observed a positive correlation between energy intake, lipid (%) and saturated fatty acids with visceral fat accumulation. CONCLUSION: NAFLD patients presented more altered clinical parameters than non-NAFLD, including the negative correlation between adiponectin and NPY/AgRP. These results suggested that NAFLD obese adolescents presented an altered inflammatory profile that can influence the neuroendocrine regulation of energy balance suggesting and additional impairment in the weigth loss therapy. Moreover, our findings showed an important influence of diet composition in the orexigenic system, being essential consider that the excessive saturated fatty acids intake could be a determinant factor to increase nonalcoholic fatty liver disease. / FAPESP: 2008/53069-0 / FAPESP: 2006/00684-3 / FAPESP (CEPID/Sono): 9814303-3 / TEDE

Connectomics – the study of neural connectivity – is primarily concerned with the mapping and characterisation of wired synaptic links; however, it is well established that long-distance chemical signalling via extrasynaptic volume transmission is also critical to brain function. As these interactions are not visible in the physical structure of the nervous system, current approaches to connectomics are unable to capture them. This work addresses the problem of missing extrasynaptic interactions by demonstrating for the first time that whole-animal volume transmission networks can be mapped from gene expression and ligand-receptor interaction data, and analysed as part of the connectome. Complete networks are presented for the monoamine systems of Caenorhabditis elegans, along with a representative sample of selected neuropeptide systems. A network analysis of the synaptic (wired) and extrasynaptic (wireless) connectomes is presented which reveals complex topological properties, including extrasynaptic rich-club organisation with interconnected hubs distinct from those in the synaptic and gap junction networks, and highly significant multilink motifs pinpointing locations in the network where aminergic and neuropeptide signalling is likely to modulate synaptic activity. Thus, the neuronal connectome can be modelled as a multiplex network with synaptic, gap junction, and neuromodulatory layers representing inter-neuronal interactions with different dynamics and polarity. This represents a prototype for understanding how extrasynaptic signalling can be integrated into connectomics research, and provides a novel dataset for the development of multilayer network algorithms.

Introdução: Os neuropeptídeos regulam uma variedade de aspectos da função nervosa e neuroendócrina, atuando através da ativação de receptores específicos da membrana celular. No sistemana nervoso central (SNC) os receptores do pepetídeo liberador de gastrina (GRPR) são amplamente expressos, e numerosos efeitos centrais têm sido descritos com a sua ativação, incluindo efeitos sobre a saciedade, regulação do ritmo circadiano, termorregulação, modulação do stress, resposta ao medo, ansiedade e memória. Pesquisas mostram que o bloqueio farmacológico do GRPR em modelos animais leva ao aparecimento de deficits na interação social, padrões restritivos de comportamento e estereotipias motoras, sintomas semelhantes ao comportamento autista em humanos, sugerindo a possibilidade de que o complexo GRP/GRPR possa ter um papel na patogênese do transtorno do espectro autista (TEA). Recentemente, dois estudos não controlados com administração do peptídeo liberador de gastrina (GRP) a 13 crianças com autismo sugeriram que ele é seguro e que possa melhorar alguns sintomas do transtorno, principalmente interação social e sintomas associados à irritabilidade. Objetivos: Comparar a eficácia, segurança, tolerabilidade do GRP em relação ao placebo em sintomas do TEA. Metodologia: Ensaio clínico crossover, randomizado, duplo-cego, controlado por placebo, com uso de GRP 160 picomol/kg por 4 dias consecutivos, em 10 crianças com autismo. Os desfechos foram medidos através da escala Aberrant Behavior Checklist (ABC). Resultados: Todos os participantes eram do sexo masculino, com idade entre 4 e 9 anos. Houve uma redução nos escores da escala ABC e suas subescalas após o uso de GRP e de placebo. Apesar dessa redução ser mais proeminente com o GRP, principalmente nas subescalas Irritabilidade, Comportamento estereotipado e Hiperatividade, não houve diferença estatística entre os resultados (p 0,334). Após uma semana da infusão, 5 crianças apresentavam melhora maior que 25% no escore total da escala ABC com uso de GRP e 2 com uso de placebo, não apresentando diferença estatística (p 0,375). Não houve efeitos adversos, alterações dos sinais vitais ou variações laboratoriais associados ao uso de GRP em nenhum paciente. Conclusões: Os resultados deste estudo, apesar do tamanho reduzido da amostra, reforçam os dados anteriores sobre a segurança do GRP no uso a curto prazo. Apesar de ter ocorrido redução dos escores da escala ABC após uso de GRP, não houve diferença estatística em relação ao placebo. Devido ao desenho crossover e tamanho pequeno da amostra do estudo atual, não foi possível esclarecer a real eficácia do GRP na redução dos sintomas do TEA na infância. Existe a necessidade de novas pesquisas com outros delineamentos e tamanho amostral maior para confirmar a eficácia e segurança do GRP em crianças com autismo. / Introduction: The neuropeptides regulate a variety of aspects of the nervous and neuroendocrine function, acting through activation of specific receptors of the cellular membrane. In system central nervous (CNS) the gastrin-releasing peptide recptors (GRPR) are widely expressed, and numerous central effects have been reported with their activation, including effects on satiety, regulating the circadian rhythm, thermoregulation, stress modulation, response to fear, anxiety and memory. Research has shown that pharmacological blockade of GRPR in animal models leads to the deficits in social interaction, restrictive patterns of behavior and motor stereotypies, autistic symptoms similar to human behavior, suggesting the possibility that the complex GRP/GRPR may have a role in the pathogenesis of autism spectrum disorder (ASD). Recently, two studies are not controlled with the administration of gastrin releasing peptide (GRP) to 13 children with autism suggest that it is safe and can improve some symptoms of the disorder, especially social interaction and symptoms associated with irritability. Objectives: To compare the efficacy, safety, tolerability GRP compared to placebo in ASD symptoms. Methodology: crossover clinical trial, randomized, double-blind, placebo-controlled, using GRP 160 picomol/kg for 4 consecutive days in 10 children with autism. Outcomes were measured by the Aberrant Behavior Checklist scale (ABC). Results: All participants were male, aged between 4 and 9 years. There was a reduction in the scores of the ABC range and its subscales after use GRP and placebo. Despite this reduction be more prominent with the GRP, particularly in subscales Irritability, Stereotypic behavior and Hyperactivity and noncompliance, there was no statistical difference between the results (p 0.334). After a week of infusion, 5 children showed improvement greater than 25% in the total score of the ABC scale in GRP use and 2 with placebo use, however there was no statistical difference (p 0.375). No adverse effects, changes in vital signs or laboratory abnormalities associated with use of GRP in any patient. Conclusions: The results of this study, despite the small sample size, reinforce previous data on the safety of the GRP in the short-term use. Although there was a reduction in ABC scale scores after use of GRP, there was no statistical difference from placebo. Due to the small sample size and design of the current study, it was not possible to clarify the real effectiveness of GRP in reducing the symptoms of ASD in childhood. There is a need for further research with other designs and larger sample size to confirm the efficacy and safety of GRP in children with autism.

Submitted by Maria Anália Conceição (marianaliaconceicao@gmail.com) on 2016-06-23T13:14:13Z No. of bitstreams: 1 Publico-NOVO-05.pdf: 1218530 bytes, checksum: 4ed86e26ba531f290cfc9a29f57fba4d (MD5) / Approved for entry into archive by Maria Anália Conceição (marianaliaconceicao@gmail.com) on 2016-06-23T13:15:03Z (GMT) No. of bitstreams: 1 Publico-NOVO-05.pdf: 1218530 bytes, checksum: 4ed86e26ba531f290cfc9a29f57fba4d (MD5) / Made available in DSpace on 2016-06-23T13:15:03Z (GMT). No. of bitstreams: 1 Publico-NOVO-05.pdf: 1218530 bytes, checksum: 4ed86e26ba531f290cfc9a29f57fba4d (MD5) Previous issue date: 2014 / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) / Introdução: A disfunção na liberação de neuropeptídeos acarreta alterações na pele, podendo gerar distúrbios no processo cicatricial e/ou afecções cutâneas. Sendo assim, a liberação de neuropeptídeos é estudada na literatura, relacionando a utilização de agentes eletrofísicos. Objetivo: Investigar o efeito da estimulação elétrica na liberação de neuropeptídeos SP e CGRP em pele de ratos. Métodos: Foram utilizados 28 animais distribuídos em 4 grupos, Grupo Controle (GC): as amostras foram coletadas após 60 minutos da tricotomia sem estímulo elétrico; Grupo Sham (GS): após 60min da tricotomia foram colocadas as placas de eletrodos com esponja umedecida com cloreto de sódio 0,9% e sobreposto na linha mediana dorsal e dispersivo na região ventral, com o aparelho desligado por 30minutos; Grupo Estimulação Elétrica com Polo Positivo (GPP): após 60 minutos da tricotomia, foi realizada a estimulação elétrica sobre a linha mediana dorsal com polaridade Positiva e o no Grupo Estimulação Elétrica com polaridade Negativa (GPN): os mesmos parâmetros utilizados acima, com a mudança, onde o polo negativo passou para linha mediana dorsal. Ao término da estimulação elétrica, foram coletadas amostras de pele, submetidas ao Western blotting para análise dos neuropeptídeos CGRP e SP. Para a análise estatística foi utilizado o teste de Análise Variância (ANOVA) para identificar a diferença entre os grupos. Resultado: Não causou diferença significante na liberação de CGRP e SP na pele de rato. Conclusão: A estimulação elétrica ultraexcitante não influenciou na liberação de neuropeptídeos, CGRP e SP, em pele de ratos. / Introduction: A dysfunction in the release of neuropeptides cause changes in the skin, and may cause disturbances in the healing process and/or skin disorders. Therefore the release of neuropeptides has been studied in the literature, connecting the use of electrophysical agents. Objective: To investigate the effect of electrical stimulation on the release of neuropeptides SP and CGRP in rat skin. Methods: 28 animals were randomly divided into 4 groups, Control Group (CG): the samples were collected 60 minutes after shaving without electrical stimulation; Sham Group (SG): after 60 minutes of trichotomy were placed electrodes plates with damp sponge with sodium chloride 0.9% and superimposed on the dorsal midline and dispersive on the ventral region, with the equipment off for 30 minutes; Electrical Stimulation Positive Pole Group (GPP): later 60 minutes of trichotomy, electrical stimulation was performed on the dorsal midline with positive polarity and the Electrical Stimulation Group with negative polarity (NPG): the same parameters used above, with the change where the negative pole was passed into the dorsal midline. At the end of electrical stimulation, skin samples, tested by Western Blotting for analysis of neuropeptides CGRP and SP, were collected. For statistical analysis, analysis of variance (ANOVA) was used to identify differences between the groups. Result: There was a minor release of neuropeptides from the negative and positive polarity, however, not significant. Conclusion: The ultra-exciting electrical stimulation did not influence the release of neuropeptides, SP and CGRP, in rat skin.

Introdução: Os neuropeptídeos regulam uma variedade de aspectos da função nervosa e neuroendócrina, atuando através da ativação de receptores específicos da membrana celular. No sistemana nervoso central (SNC) os receptores do pepetídeo liberador de gastrina (GRPR) são amplamente expressos, e numerosos efeitos centrais têm sido descritos com a sua ativação, incluindo efeitos sobre a saciedade, regulação do ritmo circadiano, termorregulação, modulação do stress, resposta ao medo, ansiedade e memória. Pesquisas mostram que o bloqueio farmacológico do GRPR em modelos animais leva ao aparecimento de deficits na interação social, padrões restritivos de comportamento e estereotipias motoras, sintomas semelhantes ao comportamento autista em humanos, sugerindo a possibilidade de que o complexo GRP/GRPR possa ter um papel na patogênese do transtorno do espectro autista (TEA). Recentemente, dois estudos não controlados com administração do peptídeo liberador de gastrina (GRP) a 13 crianças com autismo sugeriram que ele é seguro e que possa melhorar alguns sintomas do transtorno, principalmente interação social e sintomas associados à irritabilidade. Objetivos: Comparar a eficácia, segurança, tolerabilidade do GRP em relação ao placebo em sintomas do TEA. Metodologia: Ensaio clínico crossover, randomizado, duplo-cego, controlado por placebo, com uso de GRP 160 picomol/kg por 4 dias consecutivos, em 10 crianças com autismo. Os desfechos foram medidos através da escala Aberrant Behavior Checklist (ABC). Resultados: Todos os participantes eram do sexo masculino, com idade entre 4 e 9 anos. Houve uma redução nos escores da escala ABC e suas subescalas após o uso de GRP e de placebo. Apesar dessa redução ser mais proeminente com o GRP, principalmente nas subescalas Irritabilidade, Comportamento estereotipado e Hiperatividade, não houve diferença estatística entre os resultados (p 0,334). Após uma semana da infusão, 5 crianças apresentavam melhora maior que 25% no escore total da escala ABC com uso de GRP e 2 com uso de placebo, não apresentando diferença estatística (p 0,375). Não houve efeitos adversos, alterações dos sinais vitais ou variações laboratoriais associados ao uso de GRP em nenhum paciente. Conclusões: Os resultados deste estudo, apesar do tamanho reduzido da amostra, reforçam os dados anteriores sobre a segurança do GRP no uso a curto prazo. Apesar de ter ocorrido redução dos escores da escala ABC após uso de GRP, não houve diferença estatística em relação ao placebo. Devido ao desenho crossover e tamanho pequeno da amostra do estudo atual, não foi possível esclarecer a real eficácia do GRP na redução dos sintomas do TEA na infância. Existe a necessidade de novas pesquisas com outros delineamentos e tamanho amostral maior para confirmar a eficácia e segurança do GRP em crianças com autismo. / Introduction: The neuropeptides regulate a variety of aspects of the nervous and neuroendocrine function, acting through activation of specific receptors of the cellular membrane. In system central nervous (CNS) the gastrin-releasing peptide recptors (GRPR) are widely expressed, and numerous central effects have been reported with their activation, including effects on satiety, regulating the circadian rhythm, thermoregulation, stress modulation, response to fear, anxiety and memory. Research has shown that pharmacological blockade of GRPR in animal models leads to the deficits in social interaction, restrictive patterns of behavior and motor stereotypies, autistic symptoms similar to human behavior, suggesting the possibility that the complex GRP/GRPR may have a role in the pathogenesis of autism spectrum disorder (ASD). Recently, two studies are not controlled with the administration of gastrin releasing peptide (GRP) to 13 children with autism suggest that it is safe and can improve some symptoms of the disorder, especially social interaction and symptoms associated with irritability. Objectives: To compare the efficacy, safety, tolerability GRP compared to placebo in ASD symptoms. Methodology: crossover clinical trial, randomized, double-blind, placebo-controlled, using GRP 160 picomol/kg for 4 consecutive days in 10 children with autism. Outcomes were measured by the Aberrant Behavior Checklist scale (ABC). Results: All participants were male, aged between 4 and 9 years. There was a reduction in the scores of the ABC range and its subscales after use GRP and placebo. Despite this reduction be more prominent with the GRP, particularly in subscales Irritability, Stereotypic behavior and Hyperactivity and noncompliance, there was no statistical difference between the results (p 0.334). After a week of infusion, 5 children showed improvement greater than 25% in the total score of the ABC scale in GRP use and 2 with placebo use, however there was no statistical difference (p 0.375). No adverse effects, changes in vital signs or laboratory abnormalities associated with use of GRP in any patient. Conclusions: The results of this study, despite the small sample size, reinforce previous data on the safety of the GRP in the short-term use. Although there was a reduction in ABC scale scores after use of GRP, there was no statistical difference from placebo. Due to the small sample size and design of the current study, it was not possible to clarify the real effectiveness of GRP in reducing the symptoms of ASD in childhood. There is a need for further research with other designs and larger sample size to confirm the efficacy and safety of GRP in children with autism.

Introdução: Os neuropeptídeos regulam uma variedade de aspectos da função nervosa e neuroendócrina, atuando através da ativação de receptores específicos da membrana celular. No sistemana nervoso central (SNC) os receptores do pepetídeo liberador de gastrina (GRPR) são amplamente expressos, e numerosos efeitos centrais têm sido descritos com a sua ativação, incluindo efeitos sobre a saciedade, regulação do ritmo circadiano, termorregulação, modulação do stress, resposta ao medo, ansiedade e memória. Pesquisas mostram que o bloqueio farmacológico do GRPR em modelos animais leva ao aparecimento de deficits na interação social, padrões restritivos de comportamento e estereotipias motoras, sintomas semelhantes ao comportamento autista em humanos, sugerindo a possibilidade de que o complexo GRP/GRPR possa ter um papel na patogênese do transtorno do espectro autista (TEA). Recentemente, dois estudos não controlados com administração do peptídeo liberador de gastrina (GRP) a 13 crianças com autismo sugeriram que ele é seguro e que possa melhorar alguns sintomas do transtorno, principalmente interação social e sintomas associados à irritabilidade. Objetivos: Comparar a eficácia, segurança, tolerabilidade do GRP em relação ao placebo em sintomas do TEA. Metodologia: Ensaio clínico crossover, randomizado, duplo-cego, controlado por placebo, com uso de GRP 160 picomol/kg por 4 dias consecutivos, em 10 crianças com autismo. Os desfechos foram medidos através da escala Aberrant Behavior Checklist (ABC). Resultados: Todos os participantes eram do sexo masculino, com idade entre 4 e 9 anos. Houve uma redução nos escores da escala ABC e suas subescalas após o uso de GRP e de placebo. Apesar dessa redução ser mais proeminente com o GRP, principalmente nas subescalas Irritabilidade, Comportamento estereotipado e Hiperatividade, não houve diferença estatística entre os resultados (p 0,334). Após uma semana da infusão, 5 crianças apresentavam melhora maior que 25% no escore total da escala ABC com uso de GRP e 2 com uso de placebo, não apresentando diferença estatística (p 0,375). Não houve efeitos adversos, alterações dos sinais vitais ou variações laboratoriais associados ao uso de GRP em nenhum paciente. Conclusões: Os resultados deste estudo, apesar do tamanho reduzido da amostra, reforçam os dados anteriores sobre a segurança do GRP no uso a curto prazo. Apesar de ter ocorrido redução dos escores da escala ABC após uso de GRP, não houve diferença estatística em relação ao placebo. Devido ao desenho crossover e tamanho pequeno da amostra do estudo atual, não foi possível esclarecer a real eficácia do GRP na redução dos sintomas do TEA na infância. Existe a necessidade de novas pesquisas com outros delineamentos e tamanho amostral maior para confirmar a eficácia e segurança do GRP em crianças com autismo. / Introduction: The neuropeptides regulate a variety of aspects of the nervous and neuroendocrine function, acting through activation of specific receptors of the cellular membrane. In system central nervous (CNS) the gastrin-releasing peptide recptors (GRPR) are widely expressed, and numerous central effects have been reported with their activation, including effects on satiety, regulating the circadian rhythm, thermoregulation, stress modulation, response to fear, anxiety and memory. Research has shown that pharmacological blockade of GRPR in animal models leads to the deficits in social interaction, restrictive patterns of behavior and motor stereotypies, autistic symptoms similar to human behavior, suggesting the possibility that the complex GRP/GRPR may have a role in the pathogenesis of autism spectrum disorder (ASD). Recently, two studies are not controlled with the administration of gastrin releasing peptide (GRP) to 13 children with autism suggest that it is safe and can improve some symptoms of the disorder, especially social interaction and symptoms associated with irritability. Objectives: To compare the efficacy, safety, tolerability GRP compared to placebo in ASD symptoms. Methodology: crossover clinical trial, randomized, double-blind, placebo-controlled, using GRP 160 picomol/kg for 4 consecutive days in 10 children with autism. Outcomes were measured by the Aberrant Behavior Checklist scale (ABC). Results: All participants were male, aged between 4 and 9 years. There was a reduction in the scores of the ABC range and its subscales after use GRP and placebo. Despite this reduction be more prominent with the GRP, particularly in subscales Irritability, Stereotypic behavior and Hyperactivity and noncompliance, there was no statistical difference between the results (p 0.334). After a week of infusion, 5 children showed improvement greater than 25% in the total score of the ABC scale in GRP use and 2 with placebo use, however there was no statistical difference (p 0.375). No adverse effects, changes in vital signs or laboratory abnormalities associated with use of GRP in any patient. Conclusions: The results of this study, despite the small sample size, reinforce previous data on the safety of the GRP in the short-term use. Although there was a reduction in ABC scale scores after use of GRP, there was no statistical difference from placebo. Due to the small sample size and design of the current study, it was not possible to clarify the real effectiveness of GRP in reducing the symptoms of ASD in childhood. There is a need for further research with other designs and larger sample size to confirm the efficacy and safety of GRP in children with autism.

This thesis details my examination of several mechanisms for modulation of neuropeptide release via voltage-dependent and voltage-independent intraterminal signaling in isolated neurohypophysial terminals. The first part of this work characterizes depolarization-induced neuropeptide release in the absence of extracellular calcium. The goal of this project was to examine the relationship between depolarization-induced release of intracellular calcium stores and depolarization-secretion coupling of neuropeptides. We demonstrate that depolarization in the absence of extracellular calcium induced by either High K+ or electrical stimulation induces a rise in [Ca2+]i and subsequent neuropeptide release from Hypothalamic Neurohypophysial System (HNS) terminals. A portion of extracellular calcium-independent neuropeptide release is due to intraterminal calcium, but the remaining depolarization-induced release may be due to calcium-independent voltage-dependent (CIVD) release (Zhang and Zhou, 2002; Zhang et al., 2004; Yang et al., 2005). Nevertheless, our results clearly show that extracellular calcium is notnecessary for depolarization-induced neuropeptide secretion from these CNS terminals. In addition, I investigated the role of internal calcium stores in mediating μ-opioid inhibition of voltage-gated calcium channels (VGCCs). Inhibition of VGCCs via μ-opioid agonists has been shown to reduce neuropeptide release in response to High K+ stimulation of isolated terminals (Bicknell et al., 1985b; Russell et al., 1993; van Wimersma Greidanus and van de Heijning, 1993; Munro et al., 1994; Ortiz-Miranda et al., 2003; Russell et al., 2003; Ortiz-Miranda et al., 2005). My findings show μ-opioid inhibition, of VGCC and High K+-mediated rise in [Ca2+]i, are via a voltage-independent diffusible second-messenger targeting release of calcium from ryanodine-sensitive stores, possibly mediated via the cyclic ADP ribose signaling pathway. Furthermore, I detail a different intracellular messenger pathway mediating the κ-opioid inhibition of VGCC and High K+-mediated rise in [Ca2+]ii. In contrast to the μ-opioid inhibition, κ-receptor activation is coupled to a voltage-dependent membrane-delimited pathway. Inhibition of neuropeptide release via both endogenous and exogenous κ-opioid agonists has been extensively studied (Bicknell et al., 1985a; Nordmann et al., 1986a; Wammack and Racke, 1988; Munro et al., 1994; Ingram et al., 1996; Rusin et al., 1997a). My investigation shows that the κ-inhibition of VGCC is voltage-dependent and is furthermore, relieved within the context of a physiological burst of action potentials (APs). This physiologically-evoked, activity-dependent modulation of VGCC and subsequent release, represents an important mechanism for short-term synaptic plasticity at the level of the terminals. Given the ubiquitous nature of voltage-dependent G-protein signaling in the CNS, our results may prove important in understanding modulatory effects of specific bursting patterns throughout the CNS. In the last 30 years the neurohypophysial system has proven to be an excellent system to study the complexities of depolarization-secretion coupling (DSC). There have been many advances in our understanding of the underlying mechanisms involved and their physiological implications. The current work focuses on two important features of DSC; voltage and calcium. Although in many ways these two are intrinsically linked through VGCC activation, we have found that in isolated HNS terminals that is not always the case. We have further found that when voltage and calcium influx are linked during DSC, modulation by opioids may or may not be linked to activity-dependent relief depending on the opioid receptor activated. This finding has important implications in neuropeptide release during patterned stimulation in vivo. As I will discuss further, many factors play into the complexities of the regulatory mechanisms involving release. As investigations into this remarkable field continue, I hope to have contributed a valuable piece to the puzzle.